Application of euphorbia lasiocarpa extract in preparation of uric acid reducing product

Abstract

The invention relates to the technical field of plant extracts, in particular to an application of a lasiocarpum lasiocarpum extract in preparation of a uric acid reducing product. Research shows that the ethanol extracts (namely the rubus lasiocarpum crude extract), the refined components (RC1-C6) and the C1-C6 compounds of the rubus lasiocarpum and the buds have very strong inhibitory activity on xanthine oxidase, so that the uric acid level is effectively reduced, and the rubus lasiocarpum extract has the advantages of good uric acid reducing effect and small side effect, and can be used for preparing products for reducing the uric acid.

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to application of a Herba Lycopodii extract in preparing a uric acid-lowering product. Background Art

[0002] Uric acid is the final product of purine metabolism. Its production in the body mainly comes from endogenous purine synthesis and exogenous purine intake (such as purine-rich foods, such as animal offal, seafood, certain beans, etc.). Under normal circumstances, the human body excretes about two-thirds of uric acid through the kidneys and about one-third through the intestines, thereby maintaining the blood uric acid concentration in a relatively stable range. However, when the activity of key enzymes in the purine metabolism process is abnormal, such as decreased hypoxanthine-guanine phosphoribosyltransferase (HGPRT) activity, increased phosphoribosyl pyrophosphate synthetase (PRPP) activity, or when the kidney's excretion function of uric acid is impaired, it will lead to excessive production of uric acid in the blood or reduced excretion, which will lead to hyperuricemia.

[0003] With the change of people's lifestyle, including high-purine diet (such as large intake of meat, seafood, alcohol, etc.), reduced exercise, rising obesity rate and aging population, the prevalence of hyperuricemia has shown a significant upward trend. Long-term hyperuricemia can lead to the deposition of urate crystals in joints, kidneys, blood vessels and other parts, thereby causing gouty arthritis, tophi, uric acid nephropathy, cardiovascular diseases (such as coronary heart disease, hypertension, atherosclerosis, etc.) and the deterioration of metabolic syndrome-related diseases.

[0004] The clinical manifestations of gout are diverse. In acute attacks, it usually manifests as redness, swelling, heat, and pain in the joints. The pain is often extremely severe and often occurs suddenly at night. The most commonly affected joints are the first metatarsophalangeal joints, followed by ankle joints, knee joints, etc. If gout is not effectively controlled for a long time, it will lead to joint deformities, dysfunction, and even gouty nephropathy, which will seriously affect the patient's quality of life and increase the disability and mortality rates. Therefore, early intervention in time when the uric acid level is not particularly high or in the early stages of hyperuricemia, and effective control of uric acid, can effectively prevent the occurrence of diseases such as hyperuricemia or gout. Whether it is for the patient's physical health, economic burden or quality of life, it has a positive significance that cannot be ignored. It is an important concept and strategy for the prevention and treatment of diseases in modern medicine. Summary of the invention

[0005] In view of this, the present invention provides a use of a Herba Lycopodii Extract in the preparation of a uric acid-lowering product.

[0006] Use of a nephrolepis terrestris extract or at least one of the following C1-C6 compounds in the preparation of a xanthine oxidase inhibitor: Compound C1: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumarylsucrose; Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumarylsucrose; C3 compound: mumeose K; C4 compound: carotene linoleate; C5 compound: glycerol-1-eicosanoic acid-3-(4E, 7E, 10E-hexadecanoic acid); C6 compound: 2-linolenoyl-rac-glycerol; The C1~C6 compounds are extracted and separated from the ground lotus extract; The nasturtium troglodytes extract is an ethanol extract of nasturtium troglodytes and flower buds, and contains at least one of C1-C6 compounds.

[0007] Studies have shown that the ethanol extract of the ground nasturtium and flower buds (i.e., the ground nasturtium crude extract and refined components RC1-RC6) and C1-C6 compounds of the present invention have strong inhibitory activity on xanthine oxidase and can effectively reduce uric acid levels.

[0008] Xanthine oxidase (XOD) participates in the metabolism of purines, catalyzing the oxidative hydroxylation reaction of hypoxanthine and xanthine to generate uric acid (UA), and reducing oxygen in the flavin center to generate reactive oxygen. Excessive XOD activity can lead to increased uric acid production, hyperuricemia, and even gout. Therefore, XOD is an effective target for the treatment of gout and other diseases associated with hyperuricemia. Studies have reported that xanthine oxidase inhibitors are the main method for reducing serum uric acid levels in gout patients (see William B. White, MD, Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes). The mechanism of action of xanthine oxidase inhibitors is to inhibit the activity of xanthine oxidase, reduce the synthesis of uric acid, and reduce uric acid levels, thereby treating diseases caused by hyperuricemia, gout, and other hyperuricemia.

[0009] Based on this, the present invention also provides the use of a Herba Lycopodii extract or at least one of the following C1-C6 compounds in the preparation of a uric acid-lowering product: Compound C1: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumarylsucrose; Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumarylsucrose; C3 compound: mumeose K; C4 compound: carotene linoleate; C5 compound: glycerol-1-eicosanoic acid-3-(4E, 7E, 10E-hexadecanoic acid); C6 compound: 2-linolenoyl-rac-glycerol; The C1~C6 compounds are extracted and separated from the ground lotus extract; The nasturtium troglodytes extract is an ethanol extract of nasturtium troglodytes and flower buds, and contains at least one of C1-C6 compounds.

[0010] In the present invention, the uric acid-lowering product is a health food or food having the effect of lowering uric acid, or a drug for preventing and treating diseases related to hyperuricemia; The hyperuric acid-related diseases include hyperuricemia and / or gout.

[0011] In some embodiments, the extract of the Herba Lycoris Radiatae is a crude extract of the Herba Lycoris Radiatae, and the preparation method comprises: The flowers and buds of the Herba Lycoris Radiatae were extracted by cold soaking with 75% ethanol, and then concentrated to dryness under reduced pressure to obtain a crude Herba Lycoris Radiatae extract.

[0012] In some specific embodiments, the preparation method of the crude extract of the Herba Lycopodii includes: The extract was extracted with 3 times the volume of 75% ethanol / water for 3 times, each time for 24 hours, and the extract was concentrated to dryness to obtain the crude extract of Nymphaeaceae.

[0013] In other embodiments, the extract of the Herba Lycoris Radiatae is refined components RC1~RC6, RC is the abbreviation of Refined component, and the RC1~RC6 are prepared from the above-mentioned Herba Lycoris Radiatae crude extract according to the following method: the Herba Lycoris Radiatae crude extract is placed on an MCI column, and gradient elution is performed with H2O, 20% methanol solution, 40% methanol solution, 60% methanol solution, 80% methanol solution, and 100% methanol aqueous solution in sequence, with each gradient elution having 3 column volumes, to obtain the Herba Lycoris Radiatae refined components RC1-RC6, respectively.

[0014] Specifically, RC1 is the fraction eluted with water after MCI chromatography separation; RC2 is the fraction eluted with 20% methanol in water after MCI chromatography separation; RC3 is the fraction eluted with 40% methanol in water after MCI chromatography separation; RC4 is the fraction eluted with 60% methanol in water after MCI chromatography separation; RC5 is the fraction eluted with 80% methanol in water after MCI chromatography separation; RC6 is the fraction eluted with 100% methanol after MCI chromatography separation.

[0015] In the present invention, the compounds C1 to C6 (C is the abbreviation of compound) are separated from the RC2, RC3, RC4, RC5, and RC6. The specific separation method is as follows: The refined component RC2 was loaded onto a silica gel column and eluted with dichloromethane-methanol (volume ratio 9:1-8:2), petroleum ether-isopropanol (volume ratio 8:2-7:3) and ethyl acetate:methanol 9.8:0.2 to separate C4.

[0016] The refined component RC4 was loaded onto a silica gel column and eluted with dichloromethane-methanol (volume ratio 9.8:0.2-8:2), dichloromethane-isopropanol (volume ratio 9.8:0.2-9:1), and petroleum ether-isopropanol (volume ratio 8:2-6:4); the purified component RC4 was loaded onto a Sephdex column and eluted with methanol to separate C3.

[0017] The refined component RC5 was loaded onto a silica gel column and eluted with dichloromethane-acetone (volume ratio 9:1-8:2), dichloromethane-methanol (volume ratio 9:1), and petroleum ether-acetone (volume ratio 8:2-7:3) to separate C1.

[0018] The refined component RC6 was loaded onto a silica gel column and eluted with dichloromethane-methanol (volume ratio 9.8:0.2-9:1), dichloromethane-acetone, petroleum ether-acetone (volume ratio 9:1-7:3), petroleum ether-ethyl acetate (volume ratio 9:1-8:2), and loaded onto a Sephdex column with dichloromethane-methanol (volume ratio 1:1) for elution. After multiple separations, refined compounds C2, C5, and C6 were obtained.

[0019] Specifically, the name of C1 compound is 1,2',3',4',6'-O-pentaacetyl-3-O-trans-p-coumaroylsucrose, CAS No: 1392307-46-8, i.e. Mumeose D, Chinese name: 1',2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumaroylsucrose, structural formula: C 31 H 38 O 18 , the specific structure is as follows: .

[0020] Compound C2: 2', 3', 4', 6'-tetra-O-acetyl-3-O-(E)-p-coumaroyl sucrose, CAS No: 1603815-30-0, Chinese name: 2', 3', 4', 6'-tetra-O-acetyl-3-O-(E)-p-coumaroyl sucrose, structural formula: C 25 H 32 O 15 , the specific structure is as follows: .

[0021] Compound C3: mumeose K, CAS No: 2132384-01-9, Structural formula: C 25 H 32 O 15 , the specific structure is as follows: .

[0022] Compound C4: daucosterol linoleate, CAS No: 79380-30-6, Chinese name: Carotene linoleate, 3-O-(6'-O-linoleyl-β-D-glucose)-β-sitosterol; structural formula: C 53 H 90 O7, the specific structure is as follows: .

[0023] Compound C5: Glycerol 1-eicosanoate 3-(4E,7E,10E-hexadecatrienoate), CAS No: 1415934-71-2, Name: Glycerol-1-eicosanoate-3-(4E,7E,10E-hexadecatrienoate), Structural formula: C 39 H 70 O5, the specific structure is as follows: .

[0024] Compound C6: 1,3-dihydroxylpropyl-(9Z,12Z)-octadeca-9,12-dienate, CAS No: 3443-82-1; Chinese name: benfuranolol, 2-linolenoyl-rac-glycerol; Structural formula: C 21 H 38 O4, the specific structure is as follows: .

[0025] In the present invention, the effective concentration of the Herba Lycoris Radiatae Extract (Herba Lycoris Radiatae Crude Extract or Refined Components RC1-RC6) in the product is 1-100 μg / ml, specifically 1 μg / ml, 10 μg / ml, 20 μg / ml, 30 μg / ml, 40 μg / ml, 50 μg / ml, 60 μg / ml, 70 μg / ml, 80 μg / ml, 90 μg / ml, 100 μg / ml.

[0026] In the present invention, the effective concentrations of C1~C6 are independently selected from 1~100μg / ml, specifically 1μg / ml, 10μg / ml, 20μg / ml, 30μg / ml, 40μg / ml, 50μg / ml, 60μg / ml, 70μg / ml, 80μg / ml, 90μg / ml, 100μg / ml.

[0027] The present invention also provides a uric acid-lowering product, comprising at least one of the following C1-C6 compounds or a Herba Lycopodii extract, and auxiliary materials: Compound C1: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumarylsucrose; Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumarylsucrose; C3 compound: mumeose K; C4 compound: carotene linoleate; C5 compound: glycerol-1-eicosanoic acid-3-(4E, 7E, 10E-hexadecanoic acid); C6 compound: 2-linolenoyl-rac-glycerol; The C1-C6 compounds are extracted and separated from the extract of the Herba Lycoris Radiatae.

[0028] The nephrite extract contains at least one of C1-C6 compounds; The nasturtium troglodytes extract is an ethanol extract of nasturtium troglodytes and flower buds.

[0029] In the uric acid lowering product of the present invention, the preparation method of the Herba Lycopodii Extract is as described above and will not be elaborated here.

[0030] In the present invention, the product includes health care products, food or medicine.

[0031] In the present invention, the product further comprises auxiliary materials; the auxiliary materials include but are not limited to at least one of lubricants, surfactants, disintegrants, wetting agents, adhesives, fillers, excipients, absorption enhancers, adsorption carriers and diluents.

[0032] The dosage forms of the product of the present invention include tablets, capsules, granules, liquid preparations, pills or powders, etc., and any common dosage forms in the art can be used.

[0033] The present invention also provides a method for reducing uric acid, comprising: administering at least one of the Herba Lycopodii extract or C1-C6 compounds of the present invention. The present invention has no particular limitation on the manner of "administering", and a suitable manner can be determined in accordance with conventional methods in the art in combination with the preparation types described above.

[0034] The present invention also provides a method for preventing and treating uric acid lowering related diseases, comprising: administering at least one of the Herba Lycopodii extract or C1-C6 compounds of the present invention. The Herba Lycopodii extract and C1-C6 compounds are as described above. The uric acid lowering related diseases include hyperuricemia and / or gout.

[0035] Studies have shown that the crude extract of the ethanol extract of the ground nasturtium and flower bud (i.e., the ground nasturtium crude extract), refined components (RC1~RC6) and C1~C6 compounds described in the present invention all have strong inhibitory activity on xanthine oxidase, can effectively reduce uric acid levels, have the advantages of good uric acid lowering effect and small side effects, and can be used for the preparation of uric acid lowering products. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 It indicates the inhibition rate of crude extract of Herba Lysimachiae and refined components RC1~RC6 on xanthine oxidase; Figure 2 It represents the inhibition rate of crude extract and refined compounds C1~C6 of Herba Lycoris Radiatae on xanthine oxidase. DETAILED DESCRIPTION

[0037] The present invention provides the use of a Herba Lycopodii Extract in the preparation of a uric acid-lowering product. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve the desired effect. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention.

[0038] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0039] In a specific embodiment of the present invention, the crude extract of Herba Lycoris Radiatae is prepared by the following method: The flowers and buds of the ground jellyfish were taken, and cold-immersed and extracted three times with 3 times the volume of 75% ethanol aqueous solution, each time for 24 hours, and the extract was concentrated to dryness to obtain a crude extract of the ground jellyfish.

[0040] The prepared Herba Lysimachiae crude extract was made into a sample solution of required concentration and then the xanthine oxidase inhibition rate was determined.

[0041] In a specific embodiment of the present invention, the preparation method of the refined components RC1 to RC6 of the nephrite comprises: Take the flowers and buds of the ground jellyfish, use 3 times the volume of 75% ethanol aqueous solution to cold-immerse and extract 3 times, each time for 24 hours, and concentrate the extract to dryness to obtain the ground jellyfish crude extract; The crude extract of the Herba Lycoris Radiatae was loaded onto an MCI column and eluted with water, 20% methanol solution, 40% methanol solution, 60% methanol solution, 80% methanol solution and 100% methanol solution in sequence to obtain Herba Lycoris Radiatae refined components RC1 to RC6, respectively.

[0042] In the elution, each gradient elution was performed for 3 column volumes.

[0043] Specifically, RC1 is the fraction eluted with water after MCI chromatography separation; RC2 is the fraction eluted with 20% methanol in water after MCI chromatography separation; RC3 is the fraction eluted with 40% methanol in water after MCI chromatography separation; RC4 is the fraction eluted with 60% methanol in water after MCI chromatography separation; RC5 is the fraction eluted with 80% methanol in water after MCI chromatography separation; RC6 is the fraction eluted with 100% methanol after MCI chromatography separation.

[0044] The obtained refined components RC1~RC6 of the Herba Lysimachiae were prepared into sample solutions of required concentrations and then the xanthine oxidase inhibition rate was determined.

[0045] The present invention will be further described below in conjunction with embodiments: Example 1 1. Determination of xanthine oxidase inhibition rate of samples 1. Solution preparation: (1) 7× phosphate buffer (pH 7.5).

[0046] (2) 1.5 mM xanthine solution: Accurately weigh an appropriate amount of xanthine powder and prepare a solution with 7× phosphate buffer.

[0047] (3) 0.04 U / mL xanthine oxidase (XO) solution: Accurately weigh xanthine oxidase and dissolve it in 7× phosphate buffer to prepare a 0.04 U / mL enzyme solution with a working concentration of 10 mU.

[0048] (4) Allopurinol: Accurately weigh an appropriate amount of allopurinol powder and prepare a 4 mg / mL stock solution with DMSO. When required for the experiment, use 7× phosphate buffer to prepare a secondary stock solution of the corresponding concentration.

[0049] (5) Samples: Prepare the following samples as described above: crude extract of Nasturtium sphaerocephalum, refined fractions RC1 to RC6, and compounds C1 to C6. Accurately weigh appropriate amounts of samples and prepare sample solutions of corresponding concentrations using 7× phosphate buffer as required for the experiment.

[0050] 2. Prepare a 96-well plate, add 50 μL 7× phosphate buffer, 50 μL 0.04 U / mL xanthine oxidase (XO) solution and 50 μL sample solution, and incubate at 25°C for 15 min.

[0051] 3. Add 50 μL of 1.5 mM xanthine solution to start the reaction and incubate at 25°C for 8 min.

[0052] 4. Measure the absorbance (A) value at 295 nm.

[0053] 5. Sample group is As, with buffer replacing sample as blank control (Ab), phosphate buffer replacing xanthine as negative control (Ac), and allopurinol replacing sample as positive control.

[0054] 6. Xanthine oxidase inhibition rate (%) = (Ab−(As−Ac)) / Ab × 100%.

[0055] 2. Anti-xanthine oxidase effects of crude and refined fractions of Nymphaeaceae Table 1 Xanthine oxidase inhibition rate of crude extract and refined fractions of Thunbergia schrenkiana Group Xanthine oxidase inhibition rate (%) SD Allopurinol - 100 μg / ml 85.50 0.71 Allopurinol - 10 μg / ml 81.50 0.71 Allopurinol - 1 μg / ml 81.50 0.71 Crude extract of nephrite - 100μg / ml 46.50 0.71 Crude extract of nephrite - 10μg / ml 48.00 1.41 Crude extract of nephrite - 1μg / ml 77.50 0.71 RC1-100μg / ml 42.00 12.73 RC1-10μg / ml 41.50 0.71 RC1-1μg / ml 40.50 0.71 RC2-100μg / ml 49.00 1.41 RC2-10μg / ml 42.50 0.71 RC2-1μg / ml 43.50 0.71 RC3-100μg / ml 31.50 6.36 RC3-10μg / ml 43.00 1.41 RC3-1μg / ml 44.50 0.71 RC4-100μg / ml 29.00 1.41 RC4-10μg / ml 45.50 2.12 RC4-1μg / ml 47.00 1.41 RC5-100μg / ml 7.00 1.41 RC5-10μg / ml 43.50 0.71 RC5-1μg / ml 48.00 1.41 RC6-100μg / ml 38.00 2.83 RC6-10μg / ml 48.50 0.71 RC6-1μg / ml 50.00 1.41 Summary: The three concentration gradients of allopurinol showed good inhibition rates of xanthine oxidase activity, indicating that the experimental system was successful. The crude extract of Herba Lycoris and the six refined components of Herba Lycoris RC1~RC6 all showed good anti-xanthine oxidase activity, indicating that the crude extract can effectively inhibit the activity of xanthine oxidase, thereby reducing the synthesis of uric acid, lowering the level of blood uric acid, and reducing urine can be used for the preparation of uric acid-lowering products.

[0056] 3. Anti-xanthine oxidase effects of crude and refined extracts of Herba Lycoris Radiatae Table 2 Xanthine oxidase inhibition rate of crude and refined compounds of Herba Lycopodii Group Xanthine oxidase inhibition rate (%) SD Allopurinol - 100 μg / ml 85.50 0.71 Allopurinol - 10 μg / ml 81.50 0.71 Allopurinol - 1 μg / ml 81.50 0.71 Crude extract of nephrite - 100μg / ml 46.50 0.71 Crude extract of nephrite - 10μg / ml 48.00 1.41 Crude extract of nephrite - 1μg / ml 77.50 0.71 C1-100μg / ml -6.50 2.12 C1-10μg / ml 46.50 0.71 C1-1μg / ml 54.50 7.78 C2-100μg / ml 52.50 0.71 C2-10μg / ml 51.00 2.83 C2-1μg / ml 50.50 0.71 C3-100μg / ml -46.50 2.12 C3-10μg / ml 27.50 3.54 C3-1μg / ml 68.50 9.19 C4-100μg / ml 1.00 1.41 C4-10μg / ml 39.50 0.71 C4-1μg / ml 65.50 2.12 C5-100μg / ml 44.50 0.71 C5-10μg / ml 41.00 1.41 C5-1μg / ml 72.50 0.71 C6-100μg / ml 42.50 0.71 C6-10μg / ml 43.50 0.71 C6-1μg / ml 74.50 0.71 Summary: The three concentration gradients of allopurinol showed good inhibition rates of xanthine oxidase activity, indicating that the experimental system was successful. The crude extract of the Herba Lycoris Radiatae and the six Herba Lycoris Radiatae refined compounds C1~C6 all showed good anti-xanthine oxidase activity at low concentrations and had strong anti-xanthine oxidase efficacy, among which the refined compounds C5~C6 had better effects.

[0057] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a Herba Lysimachiae extract or at least one of the following C1-C6 compounds in the preparation of a uric acid-lowering product: Compound C1: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumarylsucrose; Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumarylsucrose; C3 compound: mumeose K; C4 compound: carotene linoleate; C5 compound: glycerol-1-eicosanoic acid 3-(4E, 7E, 10E-hexadecanoic acid); C6 compound: 2-linolenoyl-rac-glycerol; The C1~C6 compounds are extracted and separated from the extract of the ground lotus; The nasturtium troglodytes extract is an ethanol extract of nasturtium troglodytes and flower buds, and contains at least one of C1-C6 compounds.

2. The use according to claim 1, characterized in that: The uric acid-lowering products include: health foods, foods or drugs for preventing and treating diseases related to high uric acid that have the effect of lowering uric acid; The hyperuric acid-related diseases include hyperuricemia and / or gout.

3. Use of a Herba Lysimachiae extract or at least one of the following C1-C6 compounds in the preparation of a xanthine oxidase inhibitor: Compound C1: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumarylsucrose; Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumarylsucrose; C3 compound: mumeose K; C4 compound: carotene linoleate; C5 compound: glycerol-1-eicosanoic acid-3-(4E, 7E, 10E-hexadecanoic acid); C6 compound: 2-linolenoyl-rac-glycerol; The C1~C6 compounds are extracted and separated from the extract of the ground lotus; The nasturtium troglodytes extract is an ethanol extract of nasturtium troglodytes and flower buds, and contains at least one of C1-C6 compounds.

4. The use according to any one of claims 1 to 3, characterized in that: The preparation method of the Herba Lycopodii extract comprises: The flowers and buds of the Herba Lycoris Radiatae were extracted by cold soaking with 75% ethanol, and then concentrated to dryness under reduced pressure to obtain a crude Herba Lycoris Radiatae extract.

5. The use according to any one of claims 1 to 3, characterized in that: The preparation method of the extract of the ground jellyfish comprises: taking the flowers and buds of the ground jellyfish, cold-immersing and extracting them with 75% ethanol, and concentrating them to dryness under reduced pressure to obtain a crude extract of the ground jellyfish; applying the crude extract of the ground jellyfish to an MCI column, and gradient eluting them with water, 20% methanol solution, 40% methanol solution, 60% methanol solution, 80% methanol solution and 100% methanol aqueous solution in sequence to obtain refined components RC1-RC6 of the ground jellyfish respectively.

6. The use according to claim 1 or 3, characterized in that: The effective concentration of the Herba Lysimachiae extract in the product is 1-100 μg / ml; the effective concentrations of the C1-C6 compounds are independently selected from 1-100 μg / ml.

7. A uric acid lowering product, characterized in that: It includes a Herba Lycopodii Extract or one of the following C1-C6 compounds, and excipients: Compound C1: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumarylsucrose; Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumarylsucrose; C3 compound: mumeose K; C4 compound: carotene linoleate; C5 compound: glycerol-1-eicosanoic acid-3-(4E, 7E, 10E-hexadecanoic acid); C6 compound: 2-linolenoyl-rac-glycerol; The nephrite extract contains at least one of C1-C6 compounds; The nasturtium troglodytes extract is an ethanol extract of nasturtium troglodytes and flower buds.

8. The uric acid lowering product according to claim 7, characterized in that: The products include health products, foods or medicines.

9. The uric acid lowering product according to claim 7, characterized in that: It also includes auxiliary materials; The auxiliary materials include at least one of lubricants, surfactants, disintegrants, wetting agents, adhesives, fillers, excipients, absorption promoters, adsorption carriers and diluents.

10. The uric acid lowering product according to any one of claims 7 to 9, characterized in that: The dosage form of the product includes tablets, capsules, granules, liquid preparations, pills or powders.

Images